Alan Fram writes on Huffington Post:
Chalk one up for the pharmaceutical lobby. The U.S. drug industry fended off price curbs and other hefty restrictions in President Barack Obama’s health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage.
To be sure, the law also levies taxes and imposes other costs on pharmaceutical companies, leaving its final impact on the industry’s bottom line uncertain. A recent analysis by Goldman Sachs suggests the overhaul could mean “a manageable hit” of tens of billions of dollars over the coming decade while bolstering the value of drug-company stocks. Others expect profits, not losses, of the same magnitude.
Either way, pharmaceutical lobbyists won new federal policies they coveted and set a trajectory for long-term industry growth. Privately, several of them say their biggest triumph was heading off Democrats led by Rep. Henry Waxman, D-Calif., who wanted even more money from their industry to finance the health care system’s expansion.
Read More on the Huffington Post
Latest posts by ralph (see all)
- Fats Domino Has A Really Awesome Couch - Nov 8, 2012
- You Are Still Being Lied To: Howard Zinn’s “Columbus and Western Civilization” - Oct 8, 2012
- If ‘2001: A Space Odyssey’ Was Marketed Today (Video) - Jul 27, 2012